

CIGNA MEDICAL COVERAGE POLICIES - RADIOLOGY

Breast Imaging Guidelines

Effective Date: February 2, 2025



Instructions for use

The following coverage policy applies to health benefit plans administered by Cigna. Coverage policies are intended to provide guidance in interpreting certain standard Cigna benefit plans and are used by medical directors and other health care professionals in making medical necessity and other coverage determinations. Please note the terms of a customer's particular benefit plan document may differ significantly from the standard benefit plans upon which these coverage policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a coverage policy.

In the event of a conflict, a customer's benefit plan document always supersedes the information in the coverage policy. In the absence of federal or state coverage mandates, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of:

1. The terms of the applicable benefit plan document in effect on the date of service
2. Any applicable laws and regulations
3. Any relevant collateral source materials including coverage policies
4. The specific facts of the particular situation

Coverage policies relate exclusively to the administration of health benefit plans. Coverage policies are not recommendations for treatment and should never be used as treatment guidelines.

This evidence-based medical coverage policy has been developed by EviCore, Inc. Some information in this coverage policy may not apply to all benefit plans administered by Cigna.

These guidelines include procedures EviCore does not review for Cigna. Please refer to the **Cigna CPT code list** for the current list of high-tech imaging procedures that EviCore reviews for Cigna.

CPT® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT® five-digit codes, nomenclature and other data are copyright 2025 American Medical Association. All Rights Reserved. No fee schedules, basic units, relative values or related listings are included in the CPT book. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data contained herein or not contained herein.

Table of Contents

Guideline	Page
General Considerations (BR-Preface 1).....	3
Breast Ultrasound (BR-1).....	9
MRI Breast Coding (BR-2).....	12
Breast Reconstruction (BR-3).....	14
MRI Breast Indications (BR-5).....	17
Nipple Discharge/Galactorrhea (BR-6).....	26
Breast Pain (Mastodynia) (BR-7).....	28
Alternative Breast Imaging Approaches (BR-8).....	30
Suspected Breast Cancer in Males (BR-9).....	35
Breast Evaluation in Pregnant or Lactating Females (BR-10).....	37
Digital Breast Tomosynthesis (BR-11).....	39
Transgender Breast Cancer Supplemental Screening (BR-12).....	41
3D Rendering (BR-13).....	44
References (BR).....	46

General Considerations (BR-Preface 1)

Guideline	Page
Abbreviations for Breast Guidelines.....	4
General Guidelines (BR-Preface 1.0).....	5
BI-RADS™ Categories Chart (BR-Preface 1.1).....	6
BI-RADS™ Breast Density Categories (BR-Preface 1.2).....	8

Abbreviations for Breast Guidelines

BR.GG.Abbreviations.A

v2.0.2025

Abbreviations for Breast Guidelines	
BI-RADS™	Breast Imaging Reporting and Database System
BRCA	tumor suppressor gene
CAD	computer-aided detection
CT	computed tomography
CTA	computed tomography angiography
CTV	computed tomography venography
DCIS	ductal carcinoma in situ
FDA	Food and Drug Administration
FDG	fluorodeoxyglucose
FNA	fine needle aspiration
HRCT	high resolution computed tomography
LCIS	lobular carcinoma in situ
MRA	magnetic resonance angiography
MRI	magnetic resonance imaging
PEM	positron-emission mammography
PET	positron emission tomography

General Guidelines (BR-Preface 1.0)

BR.GG.0001.0.A

v2.0.2025

- A current clinical evaluation since the onset or change in symptoms is usually required prior to considering advanced imaging.
 - A clinical evaluation should include the following:
 - A relevant history and physical examination since the onset or change in symptoms
 - Appropriate laboratory studies and non-advanced imaging modalities, such as mammogram and/or ultrasound
 - Other meaningful contact (telephone call, electronic mail or messaging) since the onset or change in symptoms by an established individual can substitute for a face-to-face clinical evaluation
- Current clinical evaluation is not required prior to screening studies.
- Throughout this guideline, when MRI Breast is indicated any **ONE** of the following codes is supported:
 - CPT[®] 77049 MRI Breast Bilateral, including CAD, with and without contrast
 - HCPCS C8908 MRI Breast Bilateral, with and without contrast
- If the individual has breast implants, the following code is supported when MRI Breast is requested to assess integrity of breast implants **AND** is also indicated in the guidelines:
 - CPT[®] 77047 MRI Breast Bilateral, without contrast

BI-RADS™ Categories Chart (BR-Preface 1.1)

BR.GG.0001.1.A
v2.0.2025

BI-RADS™ Categories Chart	
Category	Description
Category 0: Incomplete	<p>Need additional imaging evaluation or prior mammograms for comparison.</p> <p>Category 0 classification requires that additional imaging study be specified, e.g., ultrasound, additional mammogram view, MRI.</p>
Category 1: Negative	<p>There is nothing to comment on. The breasts are symmetrical and no masses, architectural disturbances, or suspicious calcifications are present.</p>
Category 2: Benign Finding	<p>This is also a negative mammogram, but the interpreter may wish to describe a finding. Involuting, calcified fibroadenomas, multiple secretory calcifications, fat-containing lesions (such as oil cysts, lipomas, galactoceles, and mixed density hamartomas) all have characteristic appearances, and may be labeled with confidence. The interpreter might wish to describe intramammary lymph nodes, implants, etc. while still concluding that there is no mammographic evidence of malignancy.</p>

Breast Imaging Guidelines

BI-RADS™ Categories Chart	
Category	Description
Category 3: Probably Benign Finding – Short Interval Follow-up Suggested	A finding placed in this category should have a very high probability of being benign. It is not expected to change over the follow-up interval, but the radiologist would prefer to establish its stability. Data is becoming available that sheds light on the efficacy of short interval follow-up. At the present time, most approaches are intuitive. These will likely undergo future modification as more data accrue as to the validity of an approach, the interval required, and the type of findings that should be followed.
Category 4: Suspicious Abnormality – Biopsy Should Be Considered	There are lesions that do not have the characteristic morphologies of breast cancer but have a definite probability of being malignant. The radiologist has sufficient concern to urge a biopsy. If possible, the relevant possibilities should be cited so that the individual and her physician can make the decision on the ultimate course of action.
Category 5: Highly Suggestive of Malignancy – Appropriate Action Should Be Taken	These lesions have a high probability of being cancer and should be biopsied or treated surgically.
Category 6: Known Biopsy-Proven Malignancy – Appropriate Action Should Be Taken	These lesions have been biopsied and are known to be malignant.

BI-RADS™ Breast Density Categories (BR-Preface 1.2)

BR.GG.0001.2.A
v2.0.2025

BI-RADS™ Breast Density Categories
Category A: Almost entire fatty
Category B: Scattered fibroglandular densities
Category C: Heterogeneously dense
Category D: Extremely dense

Breast Ultrasound (BR-1)

Guideline	Page
Breast Ultrasound (BR-1.1).....	10

Breast Ultrasound (BR-1.1)

BR.US.0001.1.C

v2.0.2025

- Routine performance of breast ultrasound as stand-alone screening or with screening mammography is not indicated.
 - Breast ultrasound is a supplemental screening alternative for high-risk females (as described in **MRI Breast Indications [BR-5]**) with dense breasts on mammography, when MRI Breast without and with contrast cannot be performed. The inability to perform MRI Breast may be because it cannot be tolerated (i.e., insurmountable claustrophobia or body habitus), or there exists a contraindication (i.e., non-MRI compatible implantable devices or an inability to receive MRI contrast). When a MRI Breast has not been performed in the past year for high-risk screening, then a bilateral breast ultrasound requested for supplemental screening in high-risk females with dense breasts on mammography is supported.
 - Equivocal or Occult Findings:
 - Breast ultrasound (CPT[®] 76641 or CPT[®] 76642): Radiologist Report recommendation and inconclusive or conflicting findings on mammography or MRI Breast
- Breast ultrasound (CPT[®] 76641: unilateral, complete; or, CPT[®] 76642: unilateral, limited) can be used to further evaluate abnormalities found on mammogram, especially in differentiating cysts from solid lesions.
 - A clinical office visit is not necessary prior to breast ultrasound when an abnormality has been identified on a mammogram.
- BI-RADS[™] Cat 3 ultrasound follow-up imaging for stable findings at 6 months:
 - if repeat imaging remains BI-RADS[™] 3, repeat at 12 months, 18 months, and 24 months from the date of the initial imaging.
 - After 2 years of stability, the finding should be assessed as benign (Cat 2).
 - if repeat imaging is BI-RADS[™] 1 or 2, then imaging reverts to routine per individuals risk profile.
- Mammography and breast ultrasound, in any order, regardless of age for palpable breast masses or other clinical abnormalities (such as skin change, pain, nipple inversion). Ultrasound can enhance biopsy.
- For breast implant imaging, please see **Breast Implant Evaluation (BR-5.2)**.
- Axilla ultrasound (CPT[®] 76882)
 - For females with clinically suspicious lymph nodes, pre-operative axillary ultrasound with a FNA or biopsy can help identify individuals who have positive nodes.
 - See **Axillary Lymphadenopathy (and Mass) (CH-2.2)** in the Chest Imaging Guidelines.

- Bilateral should be coded CPT® 76882 x 2.
- US-guided breast biopsy (CPT® 19083) includes the imaging component
 - Additional lesions should be billed using CPT® 19084.
- Ultrasound Breast can be repeated at least 6 months after an US-directed breast biopsy to document successful lesion sampling if histology is benign and non-specific, equivocal or uncertain.
- 3D Reconstruction (CPT® 76377) is not considered medically necessary for breast ultrasound. It is commonly requested in conjunction with automated breast ultrasound (ABUS); there is no evidence to support its clinical usefulness.

MRI Breast Coding (BR-2)

Guideline	Page
MRI Breast Coding (BR-2.1).....	13

MRI Breast Coding (BR-2.1)

BR.MR.0002.1.A**v2.0.2025**

- The use of gadolinium contrast is required for the evaluation of breast parenchyma.
- The use of gadolinium contrast is **NOT** necessary for the evaluation of implant integrity in asymptomatic, average-risk individuals.
- Computer-aided detection (CAD) is included with the MRI Breast CPT[®] 77049 and CPT[®] 77048 procedures. The use of HCPCS code C8937 (CAD including computer algorithm analysis of MRI Breast data for lesion detection/characterization, pharmacokinetic analysis, with further physician review for interpretation) is **NOT** necessary with these procedures.
 - The use of CAD has little influence on the sensitivity and specificity of MRI Breast interpretation.
 - The use of HCPCS code C8937 (CAD including computer algorithm analysis of MRI Breast data for lesion detection/characterization, pharmacokinetic analysis, with further physician review for interpretation) is currently considered investigational, experimental, and/or unproven.
 - Since the CAD software automatically performs 3D imaging, CPT[®] 76376 or CPT[®] 76377 should **NOT** be used in conjunction with MRI Breast.
- MRI-guided breast biopsy (CPT[®] 19085) includes the imaging component and the needle placement under MR guidance; CPT[®] 77021 MR guidance for needle placement is **NOT** an appropriate code to bill for a breast biopsy.
 - Additional lesions should be billed using CPT[®] 19086.
 - This program does not manage codes CPT[®] 19085 or CPT[®] 19086.

Background and Supporting Information

- Although MRI Breast has superior sensitivity in identifying new unknown malignancies, it carries a significant false positive risk when compared to mammogram and ultrasound. Incidental lesions are seen on 15% of MRI Breast and increase with younger age. The percentage of incidental lesions that turn out to be malignant varies from 3% to 20% depending on the individual population. Cancer is identified by MRI Breast in only 0.7% of those with “inconclusive mammographic lesions.”

Breast Reconstruction (BR-3)

Guideline	Page
Breast Reconstruction (BR-3.1).....	15

Breast Reconstruction (BR-3.1)

BR.RC.0003.1.A

v2.0.2025

- CTA or MRA of the body part from which the free-tissue transfer flap is being taken, can be performed for breast reconstruction pre-operative planning.
 - For example, CTA Abdomen and/or Pelvis (CPT[®] 74175 or CPT[®] 72191 or CPT[®] 74174) or MRA Abdomen and/or Pelvis (CPT[®] 74185 and/or CPT[®] 72198) for Deep Inferior Epigastric Perforators (DIEP) flap.
- Routine use of CTA Chest (CPT[®] 71275) to evaluate recipient vessels is **NOT** indicated.
 - **Criteria exception:** In circumstances where there has been previous cardiac/vascular surgery and/or known vascular anomalies in the chest, it may be warranted.
- There is currently insufficient evidence-based data to support the need for routine advanced imaging for TRAM flaps or other flaps performed on a vascular pedicle.

Evidence Discussion

The American College of Radiology (ACR) Appropriateness Criteria state that either MRA abdomen and pelvis with and without IV contrast and CTA abdomen and pelvis with IV contrast are usually appropriate for preoperative planning in patients undergoing DIEP flap breast reconstruction.² Studies have found CTA mapping results in a shorter operative time when compared with no mapping in cases of breast reconstruction with free-tissue flap transfer (e.g., with Deep Inferior Epigastric Perforator (DIEP) flaps).¹

In contrast, routine use of CTA chest to evaluate for recipient vessels (often the internal mammary vessels) is not indicated. This is because a number of studies have found that the anatomy and course of these vessels is largely consistent, and that there is good concordance between surgical and radiological findings – either with ultrasound or CTA.³ CTA, however, carries with it significant risks, including contrast nephrotoxicity and allergic reactions, and the significantly higher risk of radiation exposure in the chest than in the abdomen.⁴ As such, many surgeons will use hand-held Doppler ultrasound either pre- and/or intra-operatively to evaluate recipient vessels. In certain circumstances, such as with previous surgery and/or radiation that would be expected affect the candidacy of potential recipient vessels, preoperative CTA of the chest may be considered.

As pedicled flaps, by definition, do not require a microvascular anastomosis and are not disconnected from their blood supply, there is no current evidence to support routine preoperative imaging in these patients. A recent study evaluating the use of preoperative CTA in patients undergoing pedicled TRAM flap reconstruction found that

there was no significant difference in terms of operative time nor flap loss in patients who had a preoperative CTA compared those who did not.⁵

MRI Breast Indications (BR-5)

Guideline	Page
MRI Breast Indications (BR-5.1).....	18
Breast Implant Evaluation (BR-5.2).....	23

MRI Breast Indications (BR-5.1)

BR.ID.0005.1.C

v2.0.2025

Breast MRI Considerations

- When MRI Breast imaging is clinically indicated (per the criteria listed in the sections below), an MRI Breast Bilateral with and without contrast is supported.
- MRI Breast Unilateral is **NOT** clinically supported.
- See **Breast Ultrasound (BR-1)** when there is a contraindication to MRI contrast.
- See **MRI Breast Coding (BR-2)** for MRI-guided breast biopsy.
- See **Breast Cancer (ONC-11)** in the Oncology Imaging Guidelines for imaging indications related to breast cancer as follows:
 - Breast Cancer - Initial work-up/Staging
 - Breast Cancer - Restaging/Recurrence
 - Breast Cancer - Surveillance/Follow-up
 - Annual screening with prior history of breast cancer

Malignant Phyllodes Tumor (Cystosarcoma Phyllodes)

- MRI Breast is indicated pre-operatively to establish extent of disease where a diagnosis of malignant phyllodes tumor has previously been established by tissue diagnosis.

Mammogram and/or US with Equivocal or Occult Findings

- MRI Breast is **NOT** indicated to determine biopsy recommendations for suspicious or indeterminate lesion(s) that can be readily biopsied, either using imaging guidance or physical exam, such as palpable masses and microcalcifications.
- MRI Breast is indicated for **EITHER** of the following:
 - Radiologist Report Recommendation for MRI Breast to assess inconclusive or conflicting findings on mammography or ultrasound with **EITHER** of the following:
 - Findings that are not associated with a discrete palpable mass.
 - Inconclusive findings of fat necrosis (most commonly due to trauma or surgery) in an individual with a history of breast cancer treated with surgery (lumpectomy or mastectomy with or without reconstruction).
 - Documented histopathologic discordance between core-needle biopsy findings and imaging findings. MRI Breast is indicated for further evaluation **after** the discordant biopsy (before consideration for surgical management vs. observation).
 - Discordance exists when the biopsy result does not adequately explain the abnormal (BI-RADS™ 4 or 5) findings on mammogram and/or ultrasound.
- See **MRI BI-RADS™ 3** section for lesions categorized as BI-RADS™ 3 on MRI.

- Lesions that are categorized as BI-RADS™ 3 (low risk, probably benign) **on mammogram and/or ultrasound** are not considered equivocal. MRI Breast is **NOT** indicated for these lesions.
 - Repeat the original study type (mammogram or US) in 6 months
 - if repeat imaging remains BI-RADS™ 3, repeat original study type at 12 months, 18 months, and 24 months from the date of the initial imaging.
 - After 2 years of stability, the finding should be assessed as benign (Cat 2).
 - if repeat imaging is BI-RADS™ 1 or 2, then imaging reverts to routine per individual's risk profile. See **Risk Factors** section.
- MRI Breast is **NOT** indicated for suspicious (BI-RADS™ 4 or 5) lesion on mammogram and/or ultrasound.
 - A lesion categorized as BI-RADS™ 4 or 5 should be biopsied.

MRI BI-RADS™ 3

- A probably benign lesion on **MRI** (MRI BI-RADS™ 3) should undergo repeat MRI in 6 months.
 - if repeat imaging remains MRI BI-RADS™ 3, then repeat at 12 months, 18 months, and 24 months from the date of the initial imaging.
 - After 2 years of stability, the finding should be assessed as benign (Cat 2).
 - if repeat imaging is BI-RADS™ 1 or 2, then imaging reverts to routine per individual's risk profile. See **Risk Factors** section.

Post Biopsy Imaging

- For lesions initially seen on MRI Breast **and** that have benign and non-specific, equivocal or uncertain histology (based on a stereotactic, MRI-guided, or US-directed breast biopsy), an MRI Breast can be repeated at least 6 months after the biopsy to document successful lesion sampling.

Risk Factors

- To date, evidence does not suggest improved outcomes for individuals whose only risk factor is breast density. Therefore, MRI Breast is **NOT** indicated for individuals whose only risk factor is dense breasts as determined by mammogram.
 - See **Mammogram and/or US with Equivocal or Occult Findings** section.
- Routine MRI Breast following bilateral mastectomy is **NOT** indicated (even if high-risk screening criteria may otherwise be met).
- Annual MRI Breast screening is indicated for individuals meeting the high-risk criteria in the table below:

High-Risk Indications	Age at which screening can start**
Genetic Mutations:*	

High-Risk Indications	Age at which screening can start**
Li Fraumeni (p53)	20
BRCA 1 or 2	25
STK11, Peutz-Jeghers syndrome (PJS), PTEN Mutation (Cowden Syndrome), CDH1, NF1, PALB2, ATM, CHEK2	30**
BARD1, RAD51C, RAD51D	
Personal history of atypia/LCIS:	
ADH, ALH, LCIS	At diagnosis but not prior to age 25
Family history:	
If the individual has NOT been tested for BRCA mutation and there is a first-degree relative (parent, sibling, child; half siblings are considered second-degree relatives) with BRCA 1 or BRCA 2 mutation. Annual screening is NOT indicated if the individual has been tested and is negative for BRCA 1 or BRCA 2 mutation unless they meet other criteria.	40**
Two or more first-degree relatives with breast or ovarian cancer	40**
One first-degree relative with breast cancer or ovarian cancer that was diagnosed ≤ age 50	40**
One first-degree relative with bilateral breast cancer, or both breast and ovarian cancer	40**
A first- or second-degree male relative (father, brother/half-brother, uncle, grandfather) diagnosed with breast cancer	40**
Risk by Gail (NCI), Claus, Tyrer-Cuzick (IBIS), or BRCAPRO Model:	
Clinical lifetime-risk estimated at greater than or equal to 20%	40**
Personal history of radiation therapy when younger than age 30:	

High-Risk Indications	Age at which screening can start**
Radiation to chest, whole lung, mediastinum, axilla, mantle (including mini mantle or extended mantle), total or subtotal lymphoid irradiation or total body irradiation (TBI)	25 or 8 years after completion of radiation therapy <i>whichever comes later</i>

*The following have unknown or insufficient evidence of breast cancer risk and additional MRI screening is NOT indicated at this time: MSH2, MLH1, MSH6, PMS2, EPCAM, NBN, genetic variants of unknown significance, genetic variants favoring polymorphism, and genetic variants of intermediate penetrance.

**OR 10 years prior to the age of diagnosis of the earliest relative with breast cancer (regardless of degree of relativity) *whichever comes first, but not before age 25*

Background and Supporting Information

- myRisk[®] Hereditary Cancer (Myriad Genetics, Inc.) is not accepted as a risk calculator to determine high-risk for breast cancer.
- MRI should not be used in lieu of biopsy of mammographically, clinically, and/or sonographically suspicious findings (ACR Practice Guidelines).

Evidence Discussion

High Risk Indications

Li Fraumeni Syndrome is associated with an increased incidence of premenopausal breast cancer, with the median age of diagnosis being in the early 30s.¹⁰ Accordingly, the National Institute for Health and Care Excellence⁹ recommends annual MRI screening beginning at age 20.⁹

While the American Cancer Society has found that there's not enough evidence to make a recommendation for or against screening MRI in these populations,⁶ the NCCN has recommended annual breast MRI for those with ADH, ALH or LCIS who have at least a 20% residual lifetime risk of developing breast cancer. Screening could begin at the age of diagnosis of ADH or lobular neoplasia, but not before the age of 25. They further note that the residual lifetime risk calculation depends on the age at diagnosis.⁷

BRCA1 and 2 are associated with a risk of developing breast cancer > 60%.⁸ The NCCN guidelines recommend starting MRI screening at the age of 25.⁸ *STK11* mutations are associated with a 32-54% risk of developing primary breast cancer. *CDH1* and *PALB2* mutations each confer a risk of 41-60% of developing breast cancer. NCCN guidelines recommend starting MRI screening in these patients at age 30. For patients with *NF1*, the risk of developing breast cancer is 20-40%. NCCN guidelines recommend considering annual MRI screening from ages 30-50. *ATM* mutations are associated

with a 20-30% risk of developing breast cancer, and *CHEK2* mutations similarly are associated with a 20-40% risk. NCCN guidelines suggest consideration of annual breast MRI starting at age 30-35 in both of these groups. *PTEN* mutations are associated with a 40-60% risk of developing breast cancer. While NCCN guidelines are silent on breast cancer screening for this population, ESMO guidelines recommend starting annual MRI at the age of 30.^{8,11}

BARD1, *RAD51C* and *RAD51D* are each associated with a 17-30% risk of developing breast cancer. The NCCN guidelines recommend considering an annual breast MRI starting at age 40.⁸

However, mutations and variants with a < 15% absolute risk of developing breast cancer lack sufficient evidence to suggest that screening MRI would be beneficial. Therefore, the NCCN does not recommend screening MRI for these patients unless other risks are present.⁸

The American Cancer Society considers individuals who have a first-degree relative with a BRCA 1 or 2 gene mutation and who have not been tested themselves to be at high risk. They recommend an annual MRI screening starting at age 30.⁶ On the other hand, NCCN guidelines suggest that untested individuals with a first-degree relative with a BRCA 1 or 2 mutation should start screening either 10 years before the youngest family member was diagnosed with breast cancer, but not before age 25, or at age 40, whichever comes first.⁷

MRI utilizes a magnetic field and radio waves with computer processing to produce detailed images whereas CT uses ionizing radiation. Radiation dosages vary based on many factors and can be harmful to tissues. Thus, from radiation safety perspective MRI should be utilized when appropriate and supported by existing literature; however, the NCCN also acknowledges potential harms of MRI use, such as increased false positives, increased recall, and increased benign biopsies.⁷

Phyllodes Tumor

Phyllodes tumors of the breast are usually benign, fibroepithelial lesions that have a range of biologic behaviors. Diagnosis is made by percutaneous core biopsy or excisional biopsy. MRI breast has not been shown to be of value in distinguishing phyllodes tumor from fibroadenoma. However, malignant phyllodes have the propensity to metastasize. Thus, MRI is supported in malignant phyllodes to determine the extent of disease and resectability.¹²

Breast Implant Evaluation (BR-5.2)

BR.ID.0005.2.C
v2.0.2025

Suspected Rupture of Breast Implants

- Routine surveillance imaging for asymptomatic individuals to assess the integrity of breast implants (silicone or saline) is **NOT** supported.
- Cigna does **NOT** cover surveillance MRI for breast implants if they were placed as part of purely cosmetic surgery.
- Breast MRI is **NOT** indicated for evaluation of capsular contracture.
- For suspected rupture of breast implants (saline or silicone), with a relevant equivocal clinical examination and/or conventional imaging, the imaging for further evaluation is indicated in the table below:

SALINE

Evaluation of Suspected Rupture of Breast Implant		
Saline Implants (in females or transfeminine)	Asymptomatic	Exam Equivocal For Rupture
<30	No routine imaging supported.	Ultrasound
30-39	No routine imaging supported.	Ultrasound or Diagnostic Mammogram
≥40	No routine imaging supported.	Ultrasound or Diagnostic Mammogram

If ultrasound or diagnostic mammogram results are indeterminate for saline implant rupture, additional imaging with Breast MRI without contrast (CPT® 77047) is supported for further evaluation.

SILICONE

Evaluation of Suspected Rupture of Breast Implant			
Silicone Implants (in females or transfeminine)	Asymptomatic (< 5 years after implant placement)	Asymptomatic (initial imaging at > 5 years after implant placement and follow-up imaging every 2 to 3 years after initial negative imaging)	Exam Equivocal For Rupture
All ages	No routine advanced imaging supported.	Ultrasound (further evaluation with Breast MRI without contrast (CPT® 77047) if ultrasound is indeterminate	Ultrasound OR Breast MRI without contrast (CPT® 77047)

Evidence Discussion

Breast Implant Evaluation

The two types of breast implants include saline and silicone. Saline implant rupture is more clinically apparent, since the body readily resorbs the leaking saline and the implant shell appears deflated on exam.¹³ Thus, there is no role for MRI breast(s) in asymptomatic women with saline implants.¹⁴ However, if the exam is equivocal for rupture, initial imaging supported by the American College of Radiology includes diagnostic mammogram and/or ultrasound in individuals >30 years old. In those <30 years of age, diagnostic mammogram is not typically performed and ultrasound is the initial imaging of choice.¹⁴

An exam is not as reliable for detecting the rupture of silicone implants as it is for saline implants. Therefore, if an exam is equivocal for rupture, imaging with a combination of ultrasound, mammogram, and/or MRI of the breast (with the choice of mammogram depending upon age) is appropriate.¹⁵

The initial evaluation of individuals who present with a suspicious finding on breast imaging or a palpable mass upon examination involves a biopsy (percutaneous or surgical if percutaneous is not feasible). If the biopsy results are discordant with the imaging findings, an MRI for further evaluation is supported.¹⁶

Imaging with BI-RADS assessment of category 4 require biopsy. MRI is not supported prior to biopsy.¹⁷

Imaging with BI-RADS assessment of category 3 require short-term follow up imaging: at 6, 12, and 24 months.¹⁸

Nipple Discharge/ Galactorrhea (BR-6)

Guideline	Page
Nipple Discharge/Galactorrhea (BR-6.1).....	27

Nipple Discharge/Galactorrhea (BR-6.1)

BR.DC.0006.1.A

v2.0.2025

- Pathologic nipple discharge
 - Initial imaging should include diagnostic mammogram and ultrasound (CPT[®] 76641: unilateral, complete; or, CPT[®] 76642: unilateral, limited). If these are negative or inconclusive, MRI Breast is the next appropriate imaging study.
- Physiologic nipple discharge
 - If nipple discharge is physiologic, there are no suspicious findings on clinical exam, and mammogram and ultrasound are negative, no additional imaging is necessary, and the individual can be reassured.

Background and Supporting Information

- Physiologic nipple discharge is predominantly bilateral but may be unilateral. It is commonly multi-duct. It is predominantly milky but may be white or a variety of colors including serous, yellow, green, brown, or gray. Evaluation for hyperprolactinemia can be considered.
- For milky discharge, prolactin and TSH levels are recommended to diagnose prolactinoma; pituitary imaging is not needed if normal serum Prolactin.
- Pathologic nipple discharge is defined as unilateral, bloody or serous, arising from a single duct, persistent, and spontaneous.

Evidence Discussion

No specific breast imaging is used for evaluation of physiologic discharge, other than usual screening mammogram in the appropriate age group. Otherwise, the evaluation is medical, including lab studies to rule out endocrine etiology. In a study of 13,443 women with nipple discharge, 316 (2.3%) had nonspontaneous discharge, only 1 (0.3%) of whom had carcinoma.¹⁹ Similarly, a retrospective review of 273 women who underwent diagnostic and therapeutic surgery for nipple discharge found no malignancies in those presenting with physiologic nipple discharge.²⁰

The evaluation of pathologic nipple discharge is aimed at determining if there is an underlying intraductal papilloma, high-risk lesion, or a malignancy. Larger studies estimate the rate of malignancy or high-risk histopathologic lesions to be 11% to 16% of patients with pathologic nipple discharge.²² Initial radiographic evaluation includes both diagnostic mammography and targeted breast ultrasound. If both are non-diagnostic, then MRI is the next imaging modality used for evaluation. Contrast-enhanced MRI has demonstrated sensitivities of 93 to 100 percent for invasive cancers as well as benign papillary lesions.²³

Breast Pain (Mastodynia) (BR-7)

Guideline	Page
Breast Pain (Mastodynia) (BR-7.1).....	29

Breast Pain (Mastodynia) (BR-7.1)

BR.PA.0007.1.A

v2.0.2025

- Evaluation of breast pain requires a history and physical exam.
- Mammogram and ultrasound are the initial imaging for breast pain.
- Advanced imaging is **NOT** routinely indicated in individuals with breast pain and negative mammogram and ultrasound (CPT[®] 76641: unilateral, complete; or, CPT[®] 76642: unilateral, limited).
 - If mammogram and ultrasound are not negative, see **MRI Breast Indications (BR-5)**.

Background and Supporting Information

- The risk of malignancy following a negative clinical examination (clinical breast exam, mammogram, ultrasound) has been estimated to be only 0.5%.

Evidence Discussion

In a recent study of 2820 patients presenting with breast pain, the cancer detection rate in those who underwent breast imaging was found to be 0.09%, 1% and 1.4% in patients under the age of 40, 40-49 and 50 years of age or older, respectively.²⁴ Similarly, in a case control study comparing 987 women with painful breasts and 987 controls, the prevalence of breast cancer was similar between the two groups (0.8% vs. 0.7%, respectively).²⁵ Given these data, in the absence of other factors, the American College of Radiology recommends against the use of MRI in patients with breast pain.²⁶

Alternative Breast Imaging Approaches (BR-8)

Guideline	Page
Alternative Breast Imaging Approaches (BR-8.1).....	31

Alternative Breast Imaging Approaches (BR-8.1)

BR.AA.0008.1.C

v2.0.2025

Molecular Breast Imaging (MBI)

- Molecular Breast Imaging (CPT[®] 78800) is supported in individuals who meet criteria for breast cancer screening with MRI (per **BR-5**) but for whom MRI is contraindicated.
 - See **Risk Factors** below.

Risk Factors

- To date, evidence does not suggest improved outcomes for individuals whose only risk factor is breast density. Therefore, MRI Breast is **NOT** indicated for individuals whose only risk factor is dense breasts as determined by mammogram.
 - See **Mammogram and/or US with Equivocal or Occult Findings** section.
- Routine MRI Breast following bilateral mastectomy is **NOT** indicated (even if high-risk screening criteria may otherwise be met).
- Annual MRI Breast screening is indicated for individuals meeting the high-risk criteria in the table below:

High-Risk Indications	Age at which screening can start**
Genetic Mutations:*	
Li Fraumeni (p53)	20
BRCA 1 or 2	25
STK11, Peutz-Jeghers syndrome (PJS), PTEN Mutation (Cowden Syndrome), CDH1, NF1, PALB2, ATM, CHEK2	30**
BARD1, RAD51C, RAD51D	40**
Personal history of atypia/LCIS:	
ADH, ALH, LCIS	At diagnosis but not prior to age 25
Family history:	

High-Risk Indications	Age at which screening can start**
If the individual has NOT been tested for BRCA mutation and there is a first-degree relative (parent, sibling, child; half siblings are considered second-degree relatives) with BRCA 1 or BRCA 2 mutation. Annual screening is NOT indicated if the individual has been tested and is negative for BRCA 1 or BRCA 2 mutation unless they meet other criteria.	40**
Two or more first-degree relatives with breast or ovarian cancer	40**
One first-degree relative with breast cancer or ovarian cancer that was diagnosed \leq age 50	40**
One first-degree relative with bilateral breast cancer, or both breast and ovarian cancer	40**
A first- or second-degree male relative (father, brother/half-brother, uncle, grandfather) diagnosed with breast cancer	40**
Risk by Gail (NCI), Claus, Tyrer-Cuzick (IBIS), or BRCAPRO Model:	
Clinical lifetime-risk estimated at greater than or equal to 20%	40**
Personal history of radiation therapy when younger than age 30:	
Radiation to chest, whole lung, mediastinum, axilla, mantle (including mini mantle or extended mantle), total or subtotal lymphoid irradiation or total body irradiation (TBI)	25 or 8 years after completion of radiation therapy <i>whichever comes later</i>

*The following have unknown or insufficient evidence of breast cancer risk and additional MRI screening is NOT indicated at this time: MSH2, MLH1, MSH6, PMS2, EPCAM, NBN, genetic variants of unknown significance, genetic variants favoring polymorphism, and genetic variants of intermediate penetrance.

OR 10 years prior to the age of diagnosis of the earliest relative with breast cancer (regardless of degree of relativity) *whichever comes first*, **but not before age 25

Other Alternative Breast Imaging Techniques

Other alternative breast imaging techniques may have FDA approval, but they remain investigational with respect to **BOTH** screening and diagnosis of breast cancer. These include the following:

- Nuclear breast imaging, including:
 - Scintimammography
 - Breast specific gamma imaging (BSGI)
- PET Mammography (PEM)
- Thermography
- Impedance Mammography
- Other techniques to detect oxygen consumption, light absorption, microwave transmission, nitrous oxide production
- CT Breast (CPT[®] 0633T, CPT[®] 0634T, CPT[®] 0635T, CPT[®] 0636T, CPT[®] 0637T, or CPT[®] 0638T)
- Cone Beam CT Breast

Background and Supporting Information

- CT Breast
 - CT Breast is evolving and currently being studied as a mode of breast cancer detection. It remains under investigation, and is not to be used in lieu of conventional breast imaging modalities.
- Positron Emission Mammography
 - There is currently insufficient data available to generate appropriateness criteria for this modality, and this procedure should be considered investigational at this time.
 - High-resolution positron-emission mammography (PEM) by Naviscan[™] PET Systems, also referred to as Naviscan[™] or PET mammography, performs high-resolution metabolic imaging for breast cancer using an FDG tracer. The PEM detectors are integrated into a conventional mammography system, allowing acquisition of the emission images immediately after the mammogram.
 - Requesting providers often ask for PEM as CPT[®] 78811 or “PET scan of the breast.”

Evidence Discussion

There is limited data regarding the use of MBI in individuals of average breast cancer risk. However, in those classified as high risk (lifetime risk $\geq 20\%$), the NCCN does support MBI for those who meet criteria for supplemental breast MRI, but who cannot undergo MRI.⁷

There is no data to support other alternative breast imaging techniques. They are not supported for screening by the ACR, NCCN, or other breast society guidelines. As more data becomes available, the guidelines will be updated accordingly.

The American Cancer Society considers individuals who have a first-degree relative with a BRCA 1 or 2 gene mutation and who have not been tested themselves to be at high risk. They recommend an annual MRI screening starting at age 30.⁶ On the other hand, NCCN guidelines suggest that untested individuals with a first-degree relative with a BRCA 1 or 2 mutation should start screening either 10 years before the youngest family member was diagnosed with breast cancer, but not before age 25, or at age 40, whichever comes first.⁷

Suspected Breast Cancer in Males (BR-9)

Guideline	Page
Suspected Breast Cancer in Males (BR-9.1).....	36

Suspected Breast Cancer in Males

(BR-9.1)

BR.MA.0009.1.A

v2.0.2025

See **Breast Ultrasound (BR-1)**

- There is limited evidence on the use of MRI in the evaluation of male breast disease.
- Further diagnostic pathway for suspicious clinical or imaging findings usually requires tissue diagnosis.

Background and Supporting Information

- Breast cancer in males presents as a mass, skin/nipple change, or pathologic nipple discharge.

Evidence Discussion

Breast cancer management in cis-gender males is similar to females. NCCN guidelines recommend that, for male patients presenting with bilateral breast enlargement consistent with gynecomastia or pseudogynecomastia, reassurance with clinical management of the presumed cause (e.g., drug induced, hypogonadism, hyperthyroidism, etc) is all that is needed. For male patients presenting with palpable symptoms not explained by gynecomastia, or for those presenting with bloody nipple discharge, work up should include mammography and ultrasound, followed by core needle biopsy if these studies should be found to be BIRADS category 4-5.⁷ Mammography has been found to be accurate in distinguishing benign from malignant lesions in men, and has a sensitivity and specificity of 92% and 90%, respectively, such that more advanced imaging is generally not required.²⁷

Breast Evaluation in Pregnant or Lactating Females (BR-10)

Guideline	Page
Breast Evaluation in Pregnant or Lactating Females (BR-10.1).....	38

Breast Evaluation in Pregnant or Lactating Females (BR-10.1)

BR.PR.0010.1.A

v2.0.2025

- Breast US (CPT[®] 76641 or CPT[®] 76642) is first-line imaging in pregnant and lactating females.
- If pregnant/lactating female has a palpable mass **OR** has persistent unilateral bloody nipple discharge and US is negative or suspicious, follow with diagnostic mammogram (with lead abdominal shielding).
- IV Gadolinium is required with MRI to evaluate breast parenchyma but is contraindicated in pregnancy. Biopsy, rather than advanced imaging, is recommended after inconclusive mammogram and US.
- Breast MRI without and with contrast (CPT[®] 77049) is supported for evaluation in lactating women if criteria are met otherwise (see **BR-5.1**).

Evidence Discussion

Pregnancy-associated breast cancer (PABC) is defined as breast cancer diagnosed during pregnancy, throughout the first postpartum year, or during lactation.

The most common presentation of PABC is a palpable mass, but >80% of palpable masses that are biopsied in pregnant and breastfeeding women are benign.⁸²

Given the difficulty examining the pregnant and lactating individual, diagnostic breast imaging is crucial in characterizing the features of a palpable mass. In up to 20% of lactating women, isolated bloody nipple discharge without an associated mass can occur, most commonly due to benign etiologies. However, if persistent, bloody nipple discharge can also be a sign of breast cancer. Diagnostic imaging is also recommended in these women.

Ultrasound has the highest sensitivity for the diagnosis of PABC.^{83,84} Additionally, both pregnant and lactating woman are predominantly young and have dense breast tissue. Therefore the sensitivity of mammography decreases in these women. For that reason, ultrasound is the first-line imaging in pregnant and lactating women.⁸⁴

Advanced imaging with breast MRI has a limited role in pregnant women. The IV administration of gadolinium is contraindicated. If there is clinical suspicion of malignancy, a biopsy is the next step in evaluation.^{61,85}

Digital Breast Tomosynthesis (BR-11)

Guideline	Page
Digital Breast Tomosynthesis (BR-11.1).....	40

Digital Breast Tomosynthesis (BR-11.1)

BR.BT.0011.1.C

v2.0.2025

Cigna considers digital breast tomosynthesis (DBT), also called 3D mammography, a medically appropriate imaging option in the screening of breast cancer.

- Coding Notes:
 - CPT[®] 77061: Digital breast tomosynthesis; unilateral
 - CPT[®] 77062: Digital breast tomosynthesis; bilateral
 - CPT[®] +77063: Screening digital breast tomosynthesis (used in conjunction only with screening bilateral mammography code CPT[®] 77057)
 - 3D rendering (CPT[®] 76376 or CPT[®] 76377) should **NOT** be assigned with any 3-D mammography code.

Transgender Breast Cancer Supplemental Screening (BR-12)

Guideline	Page
Transgender Breast Cancer Supplemental Screening (BR-12.1).....	42

Transgender Breast Cancer Supplemental Screening (BR-12.1)

BR.TS.0012.1.A

v2.0.2025

- Annual supplemental Ultrasound **AND/OR** MRI Breast screening is indicated for the following:
 - Transmasculine (female-to-male) with **ALL** of the following risk factors:
 - Reduction mammoplasty or no chest surgery
 - Age ≥ 25
 - High-risk ($\geq 20\%$ lifetime risk)
- Annual Ultrasound and/or MRI Breast, in addition to mammogram, for breast cancer screening is **NOT** indicated in any other scenarios, including **ANY** of the following:
 - Transfeminine (male-to-female)
 - Transmasculine (female-to-male), who have had bilateral mastectomies
 - Transmasculine (female-to-male), who have **NOT** had mastectomies **AND** are at average risk or intermediate risk
- Acceptable models of calculating clinical lifetime-risk include the following: Gail (NCI), Claus, Tyrer-Cuzick (IBIS), or BRCAPRO.

Evidence Discussion

A number of studies have found that transgender patients who have transitioned from female to male have the same risk of developing breast cancer as their cis-gendered female counterparts.²⁸⁻³⁰ As such, those who still have breast tissue (i.e., have only undergone reduction mammoplasty or no chest surgery), should be screened similarly to cis-gendered women.

The American College of Radiology Appropriateness criteria recommend the use of ultrasound and/or MRI for patients who are at intermediate to high risk based on either having a lifetime risk $\geq 20\%$, a personal history of breast cancer, lobular neoplasia or atypia, chest wall irradiation, or have a genetic predisposition to developing breast cancer.³⁰ The ACR, does however, recommend transmasculine (female-to-male) patients start screening earlier than their cis-gendered counterparts (starting at 25-30 years of age).³⁰

For transmasculine patients who are at low to average risk, mammography alone is sufficient.²⁸⁻³⁰ Patients who have had bilateral mastectomies have minimal residual breast tissue, such that breast cancer screening using imaging is not indicated.²⁸⁻³⁰

The ACR found insufficient evidence to support the use of routine MRI screening in transfeminine (male-to-female) patients, regardless of duration of hormone use and/or genetic factors. Transfeminine patients who would otherwise be considered "high risk" based on personal or family history may consider annual mammography. Similarly, mammography may be appropriate in transfeminine patients who have taken feminizing hormones for more than 5 years.³⁰

3D Rendering (BR-13)

Guideline	Page
3D Rendering (BR-13.1).....	45

3D Rendering (BR-13.1)

BR.TD.0013.1.A

v2.0.2025

- 3D rendering (CPT[®] 76376 or CPT[®] 76377) should **NOT** be used in conjunction with **ANY** 3D mammography code.
- 3D rendering (CPT[®] 76376 or CPT[®] 76377) is **NOT** indicated for breast ultrasound. It is commonly requested in conjunction with automated breast ultrasound (ABUS); there is no evidence to support its clinical usefulness.
- 3D rendering (CPT[®] 76376 or CPT[®] 76377) should **NOT** be used in conjunction with MRI Breast.

References (BR)

Guideline	Page
References (BR).....	47

References (BR)

v2.0.2025

1. Wade RG, Watford J, Wormald JCR, Bramhall RJ, Figus A. Perforator mapping reduces the operative time of DIEP flap breast reconstruction: A systematic review and meta-analysis of preoperative ultrasound, computed tomography and magnetic resonance angiography. *J Plast Reconstr Aesthet Surg*. 2018;71(4):468-477. doi:10.1016/j.bjps.2017.12.012
2. Expert Panel on Vascular Imaging, Singh N, Aghayev A, et al. ACR Appropriateness Criteria® Imaging of Deep Inferior Epigastric Arteries for Surgical Planning (Breast Reconstruction Surgery): 2022 Update. *J Am Coll Radiol*. 2022;19(11S):S357-S363. doi:10.1016/j.jacr.2022.09.004
3. Murray AC, Rozen WM, Alonso-Burgos A, Ashton MW, Garcia-Tutor E, Whitaker IS. The anatomy and variations of the internal thoracic (internal mammary) artery and implications in autologous breast reconstruction: clinical anatomical study and literature review. *Surg Radiol Anat*. 2012;34(2):159-165. doi:10.1007/s00276-011-0886-7
4. Rozen WM, Alonso-Burgos A, Murray AC, Whitaker IS. Is there a need for preoperative imaging of the internal mammary recipient site for autologous breast reconstruction?. *Ann Plast Surg*. 2013;70(1):111-115. doi:10.1097/SAP.0b013e318210874f
5. Fong A, Park HS, Ross DA, Rozen WM. Preoperative planning of unilateral breast reconstruction with pedicled transverse rectus abdominis myocutaneous (TRAM) flaps: a pilot study of perforator mapping. *Gland Surg*. 2023;12(3):366-373. doi:10.21037/gs-22-529
6. American Cancer Society Recommendations for the Early Detection of Breast Cancer. American Cancer Society. <https://www.cancer.org/cancer/types/breast-cancer/screening-tests-and-early-detection/american-cancer-society-recommendations-for-the-early-detection-of-breast-cancer.html>
7. National Comprehensive Cancer Network® (NCCN®). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Breast Cancer Screening and Diagnosis. Version 2.2024. April 9, 2024. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer Screening and Diagnosis V.2.2024. ©2024 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines® and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org.
8. National Comprehensive Cancer Network® (NCCN®). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. Version 3.2024. February 12, 2024. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic V.3.2024. ©2024 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines® and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org.
9. Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer. Clinical guideline [CG164]. National Institute for Health and Care Excellence. <https://www.nice.org.uk/guidance/cg164/chapter/recommendations#surveillance-and-strategies-for-early-detection-of-breast-cancer>
10. Olivier M, Goldgar DE, Sodha N, et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. *Cancer Res*. 2003;63(20):6643-6650.
11. Sessa C, Balmaña J, Bober SL, et al. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline. *Ann Oncol*. 2023;34(1):33-47. doi:10.1016/j.annonc.2022.10.004
12. Tan H, Zhang S, Liu H, et al. Imaging findings in phyllodes tumors of the breast. *Eur J Radiol*. 2012;81(1):e62-e69. doi:10.1016/j.ejrad.2011.01.085
13. Middleton MS. MR evaluation of breast implants. *Radiol Clin North Am*. 2014;52(3):591-608. doi:10.1016/j.rcl.2014.02.013
14. Expert Panel on Breast Imaging, Chetlen A, Niell BL, et al. ACR Appropriateness Criteria® Breast Implant Evaluation: 2023 Update. *J Am Coll Radiol*. 2023;20(11S):S329-S350. doi:10.1016/j.jacr.2023.08.019

15. Breast Implants - Certain Labeling Recommendations to Improve Patient Communication. Guidance for Industry and Food and Drug Administration Staff. U.S. Department of Health and Human Services Food and Drug Administration Center for Devices and Radiological Health. <https://www.fda.gov/media/131885/download>
16. Sanders LM, El-Madany M, Persing A, Mehta A. Use of Contrast-Enhanced MRI in Management of Discordant Core Biopsy Results. *AJR Am J Roentgenol*. 2019;212(5):1157-1165. doi:10.2214/ajr.18.20157
17. Radswiki T, Niknejad M, Yap J, et al. Breast imaging-reporting and data system (BI-RADS) assessment category 4. Reference article, Radiopaedia.org. doi:10.53347/rID-15151
18. Weerakkody Y, Kogan J, Niknejad M, et al. Breast imaging-reporting and data system (BI-RADS) assessment category 3. Reference article, Radiopaedia.org. doi:10.53347/rID-13651
19. Goksel HA, Yagmurdu MC, Demirhan B, et al. Management strategies for patients with nipple discharge. *Langenbecks Arch Surg*. 2005;390(1):52-58. doi:10.1007/s00423-004-0515-6
20. Bahl M, Baker JA, Greenup RA, Ghate SV. Diagnostic Value of Ultrasound in Female Patients With Nipple Discharge. *AJR Am J Roentgenol*. 2015;205(1):203-208. doi:10.2214/AJR.14.13354
21. Newman HF, Klein M, Northrup JD, Ray BF, Drucker M. Nipple discharge. Frequency and pathogenesis in an ambulatory population. *N Y State J Med*. 1983;83(7):928-933.
22. Simmons R, Adamovich T, Brennan M, et al. Nonsurgical evaluation of pathologic nipple discharge. *Ann Surg Oncol*. 2003;10(2):113-116. doi:10.1245/aso.2003.03.089
23. Boissierie-Lacroix M, Doutriaux-Dumoulin I, Chopier J, et al. Diagnostic accuracy of breast MRI for patients with suspicious nipple discharge and negative mammography and ultrasound: a prospective study. *Eur Radiol*. 2021;31(10):7783-7791. doi:10.1007/s00330-021-07790-4
24. Komenaka IK, Nodora J, Martinez ME, et al. Mastalgia is Not An Indication for Mammogram. *J Am Board Fam Med*. Published online September 12, 2022. doi:10.3122/jabfm.2022.AP.210476
25. Duijm LE, Guit GL, Hendriks JH, Zaat JO, Mali WP. Value of breast imaging in women with painful breasts: observational follow up study. *BMJ*. 1998;317(7171):1492-1495. doi:10.1136/bmj.317.7171.1492
26. Holbrook AI, Moy L, Akin EA, et al. ACR Appropriateness Criteria® Breast Pain. *J Am Coll Radiol*. 2018;15(11S):S276-S282. doi:10.1016/j.jacr.2018.09.014
27. Evans GF, Anthony T, Turnage RH, et al. The diagnostic accuracy of mammography in the evaluation of male breast disease [published correction appears in *Am J Surg* 2001 Jun;181(6):579]. *Am J Surg*. 2001;181(2):96-100. doi:10.1016/s0002-9610(00)00571-7
28. Sterling J, Garcia MM. Cancer screening in the transgender population: a review of current guidelines, best practices, and a proposed care model. *Transl Androl Urol*. 2020;9(6):2771-2785. doi:10.21037/tau-20-954
29. Clarke CN, Cortina CS, Fayanju OM, Dossett LA, Johnston FM, Wong SL. Breast Cancer Risk and Screening in Transgender Persons: A Call for Inclusive Care. *Ann Surg Oncol*. 2022;29(4):2176-2180. doi:10.1245/s10434-021-10217-5
30. Expert Panel on Breast Imaging, Brown A, Lourenco AP, et al. ACR Appropriateness Criteria® Transgender Breast Cancer Screening. *J Am Coll Radiol*. 2021;18(11S):S502-S515. doi:10.1016/j.jacr.2021.09.005
31. Sprague BL, Stout NK, Schechter C, et al. Benefits, Harms, and Cost-Effectiveness of Supplemental Ultrasonography Screening for Women with Dense Breasts. *Ann Intern Med*. 2015;162(3):157-166. doi:10.7326/m14-0692
32. Mendelson EB, Böhm-Vélez M, Berg WA, et al. ACR BI-RADS® Ultrasound. In: *ACR BI-RADS® Atlas, Breast imaging reporting and data system*. 5th ed. American College of Radiology. 2013.
33. Peters NH, Borel Rinkes IH, Zuithoff NP, Mali WP, Moons KG, Peeters PH. Meta-Analysis of MR imaging in the diagnosis of breast lesions. *Radiology*. 2008;246(1):116-124. doi:10.1148/radiol.2461061298
34. Moy L, Elias K, Patel V, et al. Is Breast MRI Helpful in the Evaluation of Inconclusive Mammographic Findings? *AJR Am J Roentgenol*. 2009;193(4):986-993. doi:10.2214/ajr.08.1229
35. Pinel-Giroux FM, El Khoury MM, Trop I, Bernier C, David J, Lalonde L. Breast Reconstruction: Review of Surgical Methods and Spectrum of Imaging Findings. *Radiographics*. 2013;33(2):435-453. doi:10.1148/rg.332125108
36. Dorrius MD, Jansen-van der Weide MC, van Ooijen PM, Pijnappel RM, Oudkerk M. Computer-aided detection in breast MRI: a systematic review and meta-analysis. *Eur Radiol*. 2011;21(8):1600-1608. doi:10.1007/s00330-011-2091-9

37. Lehman CD, Blume JD, DeMartini WB, Hylton NM, Herman B, Schnall MD. Accuracy and Interpretation Time of Computer-Aided Detection Among Novice and Experienced Breast MRI Readers. *AJR Am J Roentgenol*. 2013;200(6):W683-W689. doi:10.2214/ajr.11.8394
38. Saslow D, Boetes C, Burke W, et al. American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography. *CA Cancer J Clin*. 2007;57(2):75-89. doi:10.3322/canjclin.57.2.75
39. Emaus MJ, Bakker MF, Peeters PH, et al. MR Imaging as an Additional Screening Modality for the Detection of Breast Cancer in Women aged 50-75 Years with Extremely Dense Breasts: The DENSE Trial Study Design. *Radiology*. 2015;277(2):527-537. doi:10.1148/radiol.2015141827
40. Committee opinion no. 625: management of women with dense breasts diagnosed by mammography [published correction appears in *Obstet Gynecol*. 2016 Jan;127(1):166. doi: 10.1097/AOG.0000000000001228]. *Obstet Gynecol*. 2015;125(3):750-751. doi:10.1097/01.AOG.0000461763.77781.79
41. Siu AL. Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement. *Ann Intern Med*. 2016;164(4):279-296. doi:10.7326/m15-2886
42. Expert Panel on Breast Imaging, Niell BL, Jochelson MS, et al. ACR Appropriateness Criteria® Female Breast Cancer Screening: 2023 Update. *J Am Coll Radiol*. 2024;21(6S):S126-S143. doi:10.1016/j.jacr.2024.02.019
43. McCarthy CM, Pusic AL, Kerrigan CL. Silicone Breast Implants and Magnetic Resonance Imaging Screening for Rupture: Do U.S. Food and Drug Administration Recommendations Reflect an Evidence-Based Practice Approach to Patient Care? *Plast Reconstr Surg*. 2008;121(4):1127-1134. doi:10.1097/01.prs.0000302498.44244.52
44. Holmich LR, Vejborg IM, Conrad C, et al. Untreated Silicone Breast Implant Rupture. *Plast Reconstr Surg*. 2004;114(1):204-214. doi:10.1097/01.prs.0000128821.87939.b5
45. Chaney AW, Pollack A, McNeese MD, et al. Primary treatment of cystosarcoma phyllodes of the breast. *Cancer*. 2000;89(7):1502-1511. doi:10.1002/1097-0142(20001001)89:7<1502::aid-cnrc13>3.0.co;2-p
46. National Comprehensive Cancer Network® (NCCN®). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Breast Cancer. Version 4.2024. July 3, 2024. Phyllodes Tumor (PHYLL-1). Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.4.2024. ©2024 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines® and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org.
47. National Comprehensive Cancer Network® (NCCN®). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Breast Cancer Risk Reduction. Version 2.2024. March 11, 2024. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer Risk Reduction V.2.2024. ©2024 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines® and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org.
48. Morris EA, Comstock CE, Lee CH, et al. ACR BI-RADS® Magnetic Resonance Imaging. In: *ACR BI-RADS® Atlas, Breast imaging reporting and data system*. 5th ed. American College of Radiology. 2013.
49. National Comprehensive Cancer Network® (NCCN®). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Breast Cancer. Version 4.2024. July 3, 2024. Paget Disease (PAGET-1). National Comprehensive Cancer Network (NCCN) Guidelines Version 4.2024: Breast Cancer. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.4.2024. ©2024 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines® and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org.
50. Lim HS, Jeong SJ, Lee JS, et al. Paget disease of the breast: mammographic, US, and MR imaging findings with pathologic correlation. *Radiographics*. 2011;31(7):1973-1987. doi:10.1148/rg.317115070
51. Lee SJ, Trikha S, Moy L, et al. ACR Appropriateness Criteria® Evaluation of Nipple Discharge. *J Am Coll Radiol*. 2017;14(5):138-153. doi:10.1016/j.jacr.2017.01.030
52. Berger N, Luparia A, Di Leo G, et al. Diagnostic Performance of MRI versus Galactography in Women with Pathologic Nipple Discharge: A Systematic Review and Meta-Analysis. *AJR Am J Roentgenol*. 2017;209(2):465-471. doi:10.2214/ajr.16.16682
53. Bahl M, Gadd MA, Lehman CD. JOURNAL CLUB: Diagnostic Utility of MRI After Negative or Inconclusive Mammography for the Evaluation of Pathologic Nipple Discharge. *AJR Am J Roentgenol*. 2017;209(6):1404-1410. doi:10.2214/AJR.17.18139

54. Morrogh M, Morris EA, Liberman L, Borgen PI, King TA. The Predictive Value of Ductography and Magnetic Resonance Imaging in the Management of Nipple Discharge. *Ann Surg Oncol*. 2007;14(12):3369-3377. doi:10.1245/s10434-007-9530-5
55. Berg WA. Nuclear Breast Imaging: Clinical Results and Future Directions. *J Nucl Med*. 2016;57(Supplement_1):46S-52S. doi:10.2967/jnumed.115.157891
56. Lee CH, Dershaw DD, Kopans D, et al. Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer. *J Am Coll Radiol*. 2010;7(1):18-27. doi:10.1016/j.jacr.2009.09.022
57. Monticciolo DL, Newell MS, Moy L, Niell B, Monsees B, Sickles EA. Breast Cancer Screening in Women at Higher-Than-Average Risk: Recommendations From the ACR. *J Am Coll Radiol*. 2018;15(3 Pt A):408-414. doi:10.1016/j.jacr.2017.11.034.30
58. Golan O, Amitai Y, Barnea Y, Menes TS. Yield of surveillance magnetic resonance imaging after bilateral mastectomy and reconstruction: a retrospective cohort study. *Breast Cancer Res Treat*. 2018;174(2):463-468. doi:10.1007/s10549-018-05077-9
59. Sanders LM, El-Madany M, Persing A, Mehta A. Use of Contrast-Enhanced MRI in Management of Discordant Core Biopsy Results. *AJR Am J Roentgenol*. 2019;212(5):1157-1165. doi:10.2214/AJR.18.20157
60. ACR Practice Parameter for the Performance of Contrast-Enhanced Magnetic Resonance Imaging (MRI) of the Breast. Revised 2023. (Resolution 8). American College of Radiology. <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/mr-contrast-breast.pdf>.
61. Expert Panel on Breast Imaging; diFlorio-Alexander RM, Slanetz PJ, et al. ACR Appropriateness Criteria® Breast Imaging of Pregnant and Lactating Women. *J Am Coll Radiol*. 2018;15(11S):S263-S275. doi:10.1016/j.jacr.2018.09.013
62. Children's Oncology Group. Long-term follow up guidelines for survivors of childhood, adolescent and young adult cancers, version 5.0. Monrovia, CA: Children's Oncology Group; October 2018; 90. http://www.survivorshipguidelines.org/pdf/2018/COG_LTFU_Guidelines_v5.pdf.
63. Boone JM, Kwan ALC, Yang K, Burkett GW, Lindfors KK, Nelson TR. Computed Tomography for Imaging the Breast. *J Mammary Gland Biol Neoplasia*. 2006;11(2):103-111. doi:10.1007/s10911-006-9017-1
64. Boone JM, Nelson TR, Lindfors KK, Seibert JA. Dedicated Breast CT: Radiation Dose and Image Quality Evaluation. *Radiology*. 2001;221(3):657-667. doi:10.1148/radiol.2213010334
65. Diekmann F. Contrast-enhanced Dedicated Breast CT. *Radiology*. 2011;258(2):650-650. doi:10.1148/radiol.101761
66. Glick SJ. Breast CT. *Annu Rev Biomed Eng*. 2007;9(1):501-526. doi:10.1146/annurev.bioeng.9.060906.151924
67. Hendrick RE. Radiation doses and cancer risks from breast imaging studies. *Radiology*. 2010;257(1):246-253. doi:10.1148/radiol.10100570
68. Lindfors KK, Boone JM, Nelson TR, Yang K, Kwan AL, Miller DF. Dedicated breast CT: initial clinical experience. *Radiology*. 2008;246(3):725-733. doi:10.1148/radiol.2463070410
69. Prionas ND, Lindfors KK, Ray S, et al. Contrast-enhanced Dedicated Breast CT: Initial Clinical Experience. *Radiology*. 2010;256(3):714-723. doi:10.1148/radiol.10092311
70. Aminololama-Shakeri S, Abbey CK, Gazi P, et al. Differentiation of ductal carcinoma in-situ from benign micro-calcifications by dedicated breast computed tomography. *Eur J Radiol*. 2016;85(1):297-303. doi:10.1016/j.ejrad.2015.09.020
71. Aminololama-Shakeri S, Abbey CK, López JE, et al. Conspicuity of suspicious breast lesions on contrast enhanced breast CT compared to digital breast tomosynthesis and mammography. *Br J Radiol*. 2019;92(1097):20181034. doi:10.1259/bjr.20181034
72. Aminololama-Shakeri S, Hargreaves JB, Boone JM, Lindfors KK. Dedicated Breast CT: Screening Technique of the Future. *Curr Breast Cancer Rep*. 2016;8(4):242-247. doi:10.1007/s12609-016-0227-2
73. Expert Panel on Breast Imaging, Heller SL, Lourenco AP, et al. ACR Appropriateness Criteria® Imaging After Mastectomy and Breast Reconstruction. *J Am Coll Radiol*. 2020;17(11S):S403-S414. doi:10.1016/j.jacr.2020.09.009
74. Expert Panel on Breast Imaging; Mainiero MB, Moy L, et al. ACR Appropriateness Criteria® Breast Cancer Screening. *J Am Coll Radiol*. 2017;14(11S):S383-S390. doi:10.1016/j.jacr.2017.08.044

75. Expert Panel on Breast Imaging, Lewin AA, Moy L, et al. ACR Appropriateness Criteria® Stage I Breast Cancer: Initial Workup and Surveillance for Local Recurrence and Distant Metastases in Asymptomatic Women. *J Am Coll Radiol*. 2019;16(11S):S428-S439. doi:10.1016/j.jacr.2019.05.024
76. Expert Panel on Breast Imaging, Lourenco AP, Moy L, et al. ACR Appropriateness Criteria® Breast Implant Evaluation. *J Am Coll Radiol*. 2018;15(5S):S13-S25. doi:10.1016/j.jacr.2018.03.009
77. Expert Panel on Breast Imaging, Weinstein SP, Slanetz PJ, et al. ACR Appropriateness Criteria® Supplemental Breast Cancer Screening Based on Breast Density. *J Am Coll Radiol*. 2021;18(11S):S456-S473. doi:10.1016/j.jacr.2021.09.002
78. Expert Panel on Breast Imaging, Brown A, Lourenco AP, et al. ACR Appropriateness Criteria® Transgender Breast Cancer Screening. *J Am Coll Radiol*. 2021;18(11S):S502-S515. doi:10.1016/j.jacr.2021.09.005
79. Kanoi AV, Panchal KB, Sen S, Biswas G. Computed tomography angiographic study of internal mammary perforators and their use as recipient vessels for free tissue transfer in breast reconstruction. *Indian J Plast Surg*. 2017;50(01):050-055. doi:10.4103/ijps.ijps_168_16
80. Paetau AA, McLaughlin SA, McNeil RB, et al. Capsular Contracture and Possible Implant Rupture: Is Magnetic Resonance Imaging Useful? *Plast Reconstr Surg*. 2010 Mar;125(3):830-5. doi:10.1097/PRS.0b013e3181cb6066
81. ACR Practice Parameter for the Performance of Molecular Breast Imaging (MBI) Using a Dedicated Gamma Camera. Revised 2022. (Resolution 42). American College of Radiology. <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/MBI.pdf>.
82. Vashi R, Hooley R, Butler R, Geisel J, Philpotts L. Breast imaging of the pregnant and lactating patient: physiologic changes and common benign entities. *AJR Am J Roentgenol*. 2013;200(2):329-336. doi:10.2214/AJR.12.9845
83. Taylor D, Lazberger J, Ives A, Wylie E, Saunders C. Reducing delay in the diagnosis of pregnancy-associated breast cancer: how imaging can help us. *J Med Imaging Radiat Oncol*. 2011;55(1):33-42. doi:10.1111/j.1754-9485.2010.02227.x
84. Ahn BY, Kim HH, Moon WK, et al. Pregnancy- and lactation-associated breast cancer: mammographic and sonographic findings. *J Ultrasound Med*. 2003;22(5):491-499. doi:10.7863/jum.2003.22.5.491
85. Vashi R, Hooley R, Butler R, Beisel J, Philpotts L. Breast imaging of the pregnant and lactating patient: imaging modalities and pregnancy-associated breast cancer. *AJR Am J Roentgenol*. 2013;200(2):321-328. doi:10.2214/AJR.12.9814